Search results for "marker"

showing 10 items of 3799 documents

Insights into apoptotic proteins in chemotherapy: quantification techniques and informing therapy choice.

2018

Cancer is one of the leading causes of morbidity and mortality worldwide. A hallmark of cancer is evasion of apoptosis leading to tumor progression and drug resistance. Biomarker research has become a sign of the times, and proteins involved in apoptosis may be used for clinical diagnostic or prognostic purposes in cancer treatment. The recent progress in proteomic technology has triggered an emerging number of researchers to study the molecular mechanisms that regulate the apoptotic signal transduction pathways in cancer. Areas covered: A PubMed search for 'Proteomics' and 'cancer' and 'chemotherapy' and 'apoptosis' has been conducted for literature until December 2017.The study of apoptot…

0301 basic medicineProteomicsmedicine.medical_treatmentAntineoplastic AgentsApoptosisDrug resistanceProteomicsBioinformaticsBiochemistry03 medical and health sciencesMedicineAnimalsHumansPrecision MedicineMolecular BiologyChemotherapybusiness.industryCancerProteinsPrecision medicinemedicine.diseaseBiomarker (cell)030104 developmental biologyTumor progressionDrug Resistance NeoplasmSignal transductionbusinessExpert review of proteomics
researchProduct

KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting

2020

In advanced stage non-small cell lung cancer (NSCLC) patients, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) testing may soon acquire a predictive significance to select patients for AMG510 treatment. Since tissue samples are not always available, liquid biopsy may represent a viable option for KRAS testing. Here, we review the last three years clinical practice performed on 194 plasma based liquid biopsies by next generation sequencing (NGS) SiRe(®) panel. In particular, 36 (18.6%) KRAS mutated cases were identified, with an overall median allelic frequency of 5.0% (ranging between 0.2% and 46.8%). No concomitant mutations were observed in the other NSCLC clinical relevant genes includ…

0301 basic medicinePulmonary and Respiratory MedicineAMG510Settore MED/06 - Oncologia MedicaViral Oncogenemedicine.disease_cause03 medical and health sciencesBasal (phylogenetics)0302 clinical medicineG12CMedicineEpidermal growth factor receptorLiquid biopsyLung cancerneoplasmsMutationbiologyLiquid biopsybusiness.industryKirsten Rat Sarcoma Viral Oncogene Homolog (KRAS)Review Article on Improving Outcomes in Lung Cancer Through Early Diagnosis and Smoking Cessationmedicine.diseaseBasal setting030104 developmental biologyNext generation sequencing (NGS)030220 oncology & carcinogenesisCancer researchbiology.proteinBiomarker (medicine)KRASLung cancerbusiness
researchProduct

Asthmatics with high levels of serum surfactant protein D have more severe disease.

2016

Pulmonary surfactant is a mixture of lipids and surfactant-specific proteins that covers the alveolar surface, as well as the terminal conducting airways, lowering the surface tension at the air–liquid interface during breathing. The involvement of pulmonary surfactant in the pathophysiology of asthma has been suggested. An interesting working hypothesis is that the surface tension of the peripheral airways is altered in asthma, because the inflammatory process affects the structure and function of surfactant, leading to excessive airway narrowing and features of air trapping. We explored whether serum levels of surfactant protein D (SP-D) in asthmatics are related to the severity of the di…

0301 basic medicinePulmonary and Respiratory MedicineAdultMalesurfactantStatistics as TopicSevere diseasemacromolecular substancesSettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness Index03 medical and health sciences0302 clinical medicineSeverity of illnessMedicineHumansAnti-Asthmatic Agentsbusiness.industrySmall airwaysSurfactant protein DReproducibility of Resultsrespiratory systemMiddle AgedPulmonary Surfactant-Associated Protein DAsthmaRespiratory Function Tests030104 developmental biology030228 respiratory systemImmunologyBiomarker (medicine)FemalebusinessBiomarkersThe European respiratory journal
researchProduct

Exosomes as diagnostic and predictive biomarkers in lung cancer

2017

The concept of exosomes has evolved from be considered garbage bags to the demonstration that exosomes could play very interesting roles and functions, from biomarkers detection to the potential of work as drug delivery systems. It has been widely proved that exosomes can contain key molecules important for the tumour development. The current review summarizes the latest investigations developed in the field of predictive exosomal biomarkers. The microRNAs (miRNAs) are the more known molecules due to their amount inside the exosomes and the sensitivity of the techniques available for their study. However, exosomal proteins, RNA and DNA are becoming an interesting and more feasible field of …

0301 basic medicinePulmonary and Respiratory MedicineNon-small cell lung cancer (NSCLC)Review ArticleBioinformaticsExosomes03 medical and health sciencesliquid biopsies0302 clinical medicineLiquid biopsiemicroRNAmedicineLung cancerPredictive biomarkerdrug resistanceBiomarkers; Drug resistance; Exosomes; Liquid biopsies; Non-small cell lung cancer (NSCLC); Pulmonary and Respiratory Medicinebusiness.industrybiomarkersBiomarkermedicine.diseaseMicrovesiclesClinical PracticeExosomenon-small cell lung cancer (NSCLC)030104 developmental biologyTumour development030220 oncology & carcinogenesisDrug resistanceHuman medicinebusiness
researchProduct

Genome-Wide DNA Methylation Profiling in Early Stage I Lung Adenocarcinoma Reveals Predictive Aberrant Methylation in the Promoter Region of the Long…

2020

Introduction: Surgical procedure is the treatment of choice in early stage I lung adenocarcinoma. However, a considerable number of patients experience recurrence within the first 2 years after complete resection. Suitable prognostic biomarkers that identify patients at high risk of recurrence (who may probably benefit from adjuvant treatment) are still not available. This study aimed at identifying methylation markers for early recurrence that may become important tools for the development of new treatment modalities. Methods: Genome-wide DNA methylation profiling was performed on 30 stage I lung adenocarcinomas, comparing 14 patients with early metastatic recurrence with 16 patients with …

0301 basic medicinePulmonary and Respiratory MedicineOncologyLung adenocarcinomamedicine.medical_specialtyLung NeoplasmsADNAdenocarcinoma of LungMethylation profilingmedicine.disease_causeMethylation03 medical and health sciences0302 clinical medicinePrognostic markerPLUTInternal medicineBiomarkers TumorHumansMedicineddc:610Promoter Regions Geneticbusiness.industryHazard ratioPromoterMethylationDNADNA MethylationPrognosismedicine.diseaseLong non-coding RNA030104 developmental biologyDifferentially methylated regionsOncology030220 oncology & carcinogenesisIncRNACàncer de pulmóBiomarker (medicine)AdenocarcinomaRNA Long NoncodingNeoplasm Recurrence LocalLung cancerbusinessCarcinogenesisMetilació
researchProduct

Blood group antigen A type 3 expression is a favorable prognostic factor in advanced NSCLC.

2015

Abstract Objectives Several blood group-related carbohydrate antigens are prognosis-relevant markers of tumor tissues. A type 3 (repetitive A) is a blood group antigen specific for A 1 erythrocytes. Its potential expression in tumor tissues has so far not been examined. Material and methods We have evaluated its expression in normal lung and in lung cancer using a novel antibody (A69-A/E8). For comparison an anti-A antibody specific to A types 1 and 2 was used, because its expression on lung cancer tissue has been previously reported to be of prognostic relevance. Resected tissue samples of 398 NSCLC patients were analyzed in immunohistochemistry using tissue microarrays. Results and conclu…

0301 basic medicinePulmonary and Respiratory MedicineOncologyMaleCancer Researchmedicine.medical_specialtyPathologyLung Neoplasms03 medical and health sciences0302 clinical medicineAntigenAntigens NeoplasmInternal medicineCarcinoma Non-Small-Cell LungmedicineBiomarkers TumorHumansLung cancerProspective cohort studyAgedTissue microarrayLungbiologyProportional hazards modelbusiness.industrymedicine.diseasePrognosisImmunohistochemistrySurvival Analysisrespiratory tract diseases030104 developmental biologymedicine.anatomical_structureOncologyTissue Array Analysis030220 oncology & carcinogenesisbiology.proteinBlood Group AntigensImmunohistochemistryFemaleAntibodybusinessLung cancer (Amsterdam, Netherlands)
researchProduct

Accelerated telomere attrition in children and teenagers with α1-antitrypsin deficiency.

2016

Numerous studies have shown that oxidative stress accelerates telomere shortening in several lung pathologies. Since oxidative stress is involved in the pathophysiology of α1-antitrypsin deficiency (AATD), we hypothesised that telomere shortening would be accelerated in AATD patients. This study aimed to assess telomere length in AATD patients and to study its association with α1-antitrypsin phenotypes.Telomere length, telomerase activity, telomerase reverse transcriptase (hTERT) expression and biomarkers of oxidative stress were measured in 62 children and teenagers (aged 2–18 years) diagnosed with AATD and 18 controls (aged 3–16 years).Our results show that intermediate-risk (MZ; SZ) and …

0301 basic medicinePulmonary and Respiratory MedicineOncologyMalemedicine.medical_specialtyTelomeraseAdolescentmedicine.disease_causeBody Mass Index03 medical and health sciencesInternal medicinealpha 1-Antitrypsin DeficiencymedicineHumansTelomerase reverse transcriptaseChildLungTelomeraseTelomere ShorteningAlpha 1-antitrypsin deficiencybusiness.industryCase-control studyTelomeremedicine.diseaseMolecular biologyPathophysiologyTelomereOxidative Stress030104 developmental biologyPhenotypeSpirometryCase-Control StudiesChild PreschoolBiomarker (medicine)FemalebusinessOxidative stress
researchProduct

New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA

2017

Lung cancer is the second most frequent tumor and the leading cause of death by cancer in both men and women. Increasing knowledge about the cancer genome and tumor environment has led to a new setting in which morphological and molecular characterization is needed to treat patients in the most personalized way in order to achieve better outcomes. Since tumor products can be detected in body fluids, the liquid biopsy, particularly, peripheral blood, has emerged as a new source for lung cancer biomarker's analysis. A variety of tumor components can be used for this purpose. Among them, circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) should be especially considered. Different…

0301 basic medicinePulmonary and Respiratory MedicineOncologymedicine.medical_specialtybiologybusiness.industrynon-small cell lung cancer (NSCLC)CancerReview Articlemedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineCirculating tumor cellCell-free fetal DNA030220 oncology & carcinogenesisInternal medicineImmunologymedicinebiology.proteinBiomarker (medicine)Epidermal growth factor receptorLiquid biopsyLung cancerbusiness
researchProduct

P3.02c-046 Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC

2017

0301 basic medicinePulmonary and Respiratory MedicineOncologymedicine.medical_specialtybusiness.industry03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyAtezolizumab030220 oncology & carcinogenesisInternal medicineMedicineBiomarker (medicine)Erlotinibbusinessmedicine.drugJournal of Thoracic Oncology
researchProduct

Heat shock protein-90 toward theranostics: a breath of fresh air in idiopathic pulmonary fibrosis.

2017

Heat shock proteins are potential biomarkers and therapeutic targets in idiopathic pulmonary fibrosis http://ow.ly/fHVP30hJUOl

0301 basic medicinePulmonary and Respiratory MedicinePathologymedicine.medical_specialtyTheranostic NanomedicinePulmonary FibrosisRespiratory SystemHSP90 Heat-Shock ProteinsTheranostic Nanomedicine03 medical and health sciencesIdiopathic pulmonary fibrosisFresh airHeat shock proteinPulmonary fibrosisMedicineHumansHSP90 Heat-Shock ProteinsRespiratory systemMyofibroblastsHeat-Shock Proteinsbusiness.industrymedicine.diseaseIdiopathic Pulmonary Fibrosis030104 developmental biologyPotential biomarkersbusinessThe European respiratory journal
researchProduct